<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102841</url>
  </required_header>
  <id_info>
    <org_study_id>13/0410</org_study_id>
    <secondary_id>14/LO/0243</secondary_id>
    <nct_id>NCT02102841</nct_id>
  </id_info>
  <brief_title>Investigating Immune Mechanisms in Atopic Eczema</brief_title>
  <official_title>Investigating the Role of Skin Resident T Cells in Atopic Eczema and Responses to Antigen Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermatrust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the mechanisms behind the immune dysfunction that&#xD;
      occurs in atopic eczema (or atopic dermatitis).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atopic eczema is a chronic inflammatory skin disease that affects 15-20% of children and 12%&#xD;
      of adults and leads to significant loss of quality of life. It results from a complex&#xD;
      interaction of genetic and environmental factors, and is characterised by dysregulation of&#xD;
      the cutaneous immune system. Specifically, in the skin of eczema patients there is a&#xD;
      persistence of T lymphocytes (a crucial cell involved in regulating the immune system), and&#xD;
      an overproduction of certain cytokines (signalling molecules that are essential in producing&#xD;
      inflammatory responses).&#xD;
&#xD;
      The study intends to investigate the causes of atopic eczema by examining the number,&#xD;
      characteristics and function of T lymphocytes in the skin and the blood of eczema patients,&#xD;
      as well as the types of cytokine they produce. To achieve this the investigators aim to take&#xD;
      skin biopsies, tissue fluid (from induced skin suction blisters) and blood samples from adult&#xD;
      eczema patients and healthy controls for analysis. Additionally, in these groups a cutaneous&#xD;
      immune response will be initiated by injecting tuberculin protein purified derivative (the&#xD;
      Mantoux test) into the skin, to further investigate how the behaviour of T lymphocytes varies&#xD;
      between eczema patients and healthy controls.&#xD;
&#xD;
      This research is important in view of the high prevalence of atopic eczema in the population.&#xD;
      An improved understanding of its causes will hopefully lead to more effective treatments for&#xD;
      this condition in future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Recruitment no longer feasible&#xD;
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Skin biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mm skin punch biopsy on forearm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skin suction blister</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin suction blister induced on forearm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantoux, skin biopsy, suction blister</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <arm_group_label>Mantoux, skin biopsy, suction blister</arm_group_label>
    <arm_group_label>Skin biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin suction blister</intervention_name>
    <arm_group_label>Mantoux, skin biopsy, suction blister</arm_group_label>
    <arm_group_label>Skin suction blister</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mantoux test</intervention_name>
    <arm_group_label>Mantoux, skin biopsy, suction blister</arm_group_label>
    <other_name>Tuberculin PPD (SSI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of atopic dermatitis (according to United Kingdom Working Party's diagnostic&#xD;
             criteria)&#xD;
&#xD;
          -  Previous Bacillus Calmette-Guerin vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give written informed consent&#xD;
&#xD;
          -  Previous history of hypersensitivity to local anaesthetic (for skin biopsy) or&#xD;
             tuberculin PPD (for skin test)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  History of tuberculosis&#xD;
&#xD;
          -  Recent infection or immunisation (within last month)&#xD;
&#xD;
          -  Known immunodeficiency e.g. HIV infection, primary immunodeficiency, any history of&#xD;
             chemotherapy or radiotherapy&#xD;
&#xD;
          -  Systemic steroids within the last month or any other immunosuppressive medications&#xD;
             (eg. methotrexate, ciclosporin or azathioprine) within the previous 3 months&#xD;
&#xD;
          -  Phototherapy within the previous 28 days&#xD;
&#xD;
          -  Treatment with potent topical corticosteroids or tacrolimus ointment within the&#xD;
             previous 7 days&#xD;
&#xD;
          -  Significant co-morbidity (diabetes, renal failure, liver failure, heart failure)&#xD;
&#xD;
          -  On warfarin or known bleeding disorder&#xD;
&#xD;
          -  History of neoplasm in last 10 years (not including basal cell carcinoma)&#xD;
&#xD;
          -  Previous keloid scarring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Rustin, MBBS MRCP MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free London NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994 Sep;131(3):383-96.</citation>
    <PMID>7918015</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

